These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9876958)

  • 21. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
    Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
    Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.
    Lenz RA; Pritchett YL; Berry SM; Llano DA; Han S; Berry DA; Sadowsky CH; Abi-Saab WM; Saltarelli MD
    Alzheimer Dis Assoc Disord; 2015; 29(3):192-9. PubMed ID: 25973909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
    Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease.
    Le Bars PL; Velasco FM; Ferguson JM; Dessain EC; Kieser M; Hoerr R
    Neuropsychobiology; 2002; 45(1):19-26. PubMed ID: 11803237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial.
    Kanowski S; Hoerr R
    Pharmacopsychiatry; 2003 Nov; 36(6):297-303. PubMed ID: 14663654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.
    Egan M; Yaari R; Liu L; Ryan M; Peng Y; Lines C; Michelson D
    Curr Alzheimer Res; 2012 May; 9(4):481-90. PubMed ID: 22272611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia.
    Le Bars PL; Kieser M; Itil KZ
    Dement Geriatr Cogn Disord; 2000; 11(4):230-7. PubMed ID: 10867450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
    Stein MS; Scherer SC; Ladd KS; Harrison LC
    J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
    Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease.
    Maher-Edwards G; Zvartau-Hind M; Hunter AJ; Gold M; Hopton G; Jacobs G; Davy M; Williams P
    Curr Alzheimer Res; 2010 Aug; 7(5):374-85. PubMed ID: 20043816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.